These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 20473900)

  • 1. Curcumin enhances dasatinib-induced inhibition of growth and transformation of colon cancer cells.
    Nautiyal J; Banerjee S; Kanwar SS; Yu Y; Patel BB; Sarkar FH; Majumdar AP
    Int J Cancer; 2011 Feb; 128(4):951-61. PubMed ID: 20473900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Src inhibitor dasatinib inhibits growth of breast cancer cells by modulating EGFR signaling.
    Nautiyal J; Majumder P; Patel BB; Lee FY; Majumdar AP
    Cancer Lett; 2009 Oct; 283(2):143-51. PubMed ID: 19398150
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined Inhibition of IGF-1R/IR and Src family kinases enhances antitumor effects in prostate cancer by decreasing activated survival pathways.
    Dayyani F; Parikh NU; Varkaris AS; Song JH; Moorthy S; Chatterji T; Maity SN; Wolfe AR; Carboni JM; Gottardis MM; Logothetis CJ; Gallick GE
    PLoS One; 2012; 7(12):e51189. PubMed ID: 23300537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress.
    Kopetz S; Lesslie DP; Dallas NA; Park SI; Johnson M; Parikh NU; Kim MP; Abbruzzese JL; Ellis LM; Chandra J; Gallick GE
    Cancer Res; 2009 May; 69(9):3842-9. PubMed ID: 19383922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ErbB-inhibitory protein: a modified ectodomain of epidermal growth factor receptor synergizes with dasatinib to inhibit growth of breast cancer cells.
    Nautiyal J; Yu Y; Aboukameel A; Kanwar SS; Das JK; Du J; Patel BB; Sarkar FH; Rishi AK; Mohammad RM; Majumdar AP
    Mol Cancer Ther; 2010 Jun; 9(6):1503-14. PubMed ID: 20515951
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms of curcumin- and EGF-receptor related protein (ERRP)-dependent growth inhibition of colon cancer cells.
    Reddy S; Rishi AK; Xu H; Levi E; Sarkar FH; Majumdar AP
    Nutr Cancer; 2006; 55(2):185-94. PubMed ID: 17044774
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells.
    Johnson FM; Saigal B; Talpaz M; Donato NJ
    Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6924-32. PubMed ID: 16203784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors.
    Montero JC; Seoane S; Ocaña A; Pandiella A
    Clin Cancer Res; 2011 Sep; 17(17):5546-52. PubMed ID: 21670084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of potential biomarkers for measuring inhibition of Src kinase activity in colon cancer cells following treatment with dasatinib.
    Serrels A; Macpherson IR; Evans TR; Lee FY; Clark EA; Sansom OJ; Ashton GH; Frame MC; Brunton VG
    Mol Cancer Ther; 2006 Dec; 5(12):3014-22. PubMed ID: 17148760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of p27(Kip1) in dasatinib-enhanced paclitaxel cytotoxicity in human ovarian cancer cells.
    Le XF; Mao W; He G; Claret FX; Xia W; Ahmed AA; Hung MC; Siddik ZH; Bast RC
    J Natl Cancer Inst; 2011 Sep; 103(18):1403-22. PubMed ID: 21813412
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Curcumin targets FOLFOX-surviving colon cancer cells via inhibition of EGFRs and IGF-1R.
    Patel BB; Gupta D; Elliott AA; Sengupta V; Yu Y; Majumdar AP
    Anticancer Res; 2010 Feb; 30(2):319-25. PubMed ID: 20332435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of cell growth and up-regulation of MAD2 in human oesophageal squamous cell carcinoma after treatment with the Src/Abl inhibitor dasatinib.
    Wang L; Guo B; Wang R; Jiang Y; Qin S; Liang S; Zhao Y; Guo W; Li K; Fan X
    Clin Sci (Lond); 2012 Jan; 122(1):13-24. PubMed ID: 21751967
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines.
    Eustace AJ; Crown J; Clynes M; O'Donovan N
    J Transl Med; 2008 Sep; 6():53. PubMed ID: 18823558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting tyrosine-kinases and estrogen receptor abrogates resistance to endocrine therapy in breast cancer.
    Liu S; Meng X; Chen H; Liu W; Miller T; Murph M; Lu Y; Zhang F; Gagea M; Arteaga CL; Mills GB; Meric-Bernstam F; González-Angulo AM
    Oncotarget; 2014 Oct; 5(19):9049-64. PubMed ID: 24979294
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Wnt5a promotes human colon cancer cell migration and invasion but does not augment intestinal tumorigenesis in Apc1638N mice.
    Bakker ER; Das AM; Helvensteijn W; Franken PF; Swagemakers S; van der Valk MA; ten Hagen TL; Kuipers EJ; van Veelen W; Smits R
    Carcinogenesis; 2013 Nov; 34(11):2629-38. PubMed ID: 23764752
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells.
    Nam S; Kim D; Cheng JQ; Zhang S; Lee JH; Buettner R; Mirosevich J; Lee FY; Jove R
    Cancer Res; 2005 Oct; 65(20):9185-9. PubMed ID: 16230377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of lysyl oxidase in SRC-dependent proliferation and metastasis of colorectal cancer.
    Baker AM; Cox TR; Bird D; Lang G; Murray GI; Sun XF; Southall SM; Wilson JR; Erler JT
    J Natl Cancer Inst; 2011 Mar; 103(5):407-24. PubMed ID: 21282564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dasatinib inhibits mammary tumour development in a genetically engineered mouse model.
    Karim SA; Creedon H; Patel H; Carragher NO; Morton JP; Muller WJ; Evans TR; Gusterson B; Sansom OJ; Brunton VG
    J Pathol; 2013 Aug; 230(4):430-40. PubMed ID: 23616343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of anti-proliferative and chemosensitizing effects of sunitinib on human esophagogastric cancer cells: Synergistic interaction with vandetanib via inhibition of multi-receptor tyrosine kinase pathways.
    Lyros O; Mueller A; Heidel F; Schimanski CC; Gockel I; Galle PR; Lang H; Moehler M
    Int J Cancer; 2010 Sep; 127(5):1197-208. PubMed ID: 20039326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular mechanisms of action and potential biomarkers of growth inhibition of dasatinib (BMS-354825) on hepatocellular carcinoma cells.
    Chang AY; Wang M
    BMC Cancer; 2013 May; 13():267. PubMed ID: 23721490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.